Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Ip2ipo Portfolio L.P. Acting By Its General Partner Ip2ipo Portfolio (Gp) Limited investment portfolio
Ip2ipo Portfolio L.P. Acting By Its General Partner Ip2ipo Portfolio (Gp) Limited has made numerous investments in companies such as Storm Therapeutics, Helio Display Materials, and Azuri Technologies within the Biotech sector.
unknown
Portfolio
3
Team
0
Portfolio (3)
| Company | Sector | City | Source | Last confirmed on |
|---|---|---|---|---|
| Azuri Technologies Ltd AZURI TECHNOLOGIES LTD provides off-grid solar energy solutions, including solar home systems and solar-powered televisions, which offer lighting, phone charging, radio, and satellite TV. The company primarily targets rural, off-grid households in Sub-Saharan Africa. | Industrials & Manufacturing | Cambridge | Confirmed | 2026-06-24 |
| Helio Display Materials Limited Helio Display Materials Limited develops perovskite‑based colour‑conversion materials for micro‑display and other display technologies, leveraging patents licensed from Oxford and Cambridge universities and scaling production toward pilot‑scale manufacturing. Its products target display manufacturers seeking higher conversion efficiency, narrow emission spectra and greater optical density. | Healthcare & Life Sciences | Oxford | Confirmed | 2025-11-28 |
Backs Similar Companies
Investors who tend to invest in the same sort of companies.
5 more similar investors hiddenSign up to unlock →
Shareholding changes (5)
Ip2ipo Portfolio L.P. Acting By Its General Partner Ip2ipo Portfolio (Gp) Limited's positions across portfolio companies2026
- PREFERRED 0 → 9,525,879
- ORDINARY 0 → 2,456,508
2025
- C1 PREFERRED 0 → 12,511,113
- C2 PREFERRED 0 → 9,345,032
Articles (2)
- Axia Power Holdings BV and PM Equity Partner SARL exit Azuri Technologies Ltd with 42.1% and 17.2% holdings gone; UK FF Nominees Limited takes 11%23 Aug 2026Azuri Technologies
- Storm Therapeutics secures £9.2m for clinical stage RNA research9 May 2026Storm Therapeutics